GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OCSE:ZEAL) » Definitions » Gross-Profit-to-Asset %

Zealand Pharma A/S (OCSE:ZEAL) Gross-Profit-to-Asset % : 1.78% (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Zealand Pharma A/S Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Zealand Pharma A/S's annualized Gross Profit for the quarter that ended in Dec. 2023 was kr36.9 Mil. Zealand Pharma A/S's average Total Assets over the quarter that ended in Dec. 2023 was kr2,077.7 Mil. Therefore, Zealand Pharma A/S's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 1.78%.


Zealand Pharma A/S Gross-Profit-to-Asset % Historical Data

The historical data trend for Zealand Pharma A/S's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Gross-Profit-to-Asset % Chart

Zealand Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.95 11.63 5.10 5.77 18.39

Zealand Pharma A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.27 3.79 2.46 54.98 1.78

Competitive Comparison of Zealand Pharma A/S's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Zealand Pharma A/S's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Gross-Profit-to-Asset % falls into.



Zealand Pharma A/S Gross-Profit-to-Asset % Calculation

Zealand Pharma A/S's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=323.614/( (1539.806+1979.993)/ 2 )
=323.614/1759.8995
=18.39 %

Zealand Pharma A/S's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=36.892/( (2175.505+1979.993)/ 2 )
=36.892/2077.749
=1.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Zealand Pharma A/S Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (OCSE:ZEAL) Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.